JP2008506758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008506758A5 JP2008506758A5 JP2007522013A JP2007522013A JP2008506758A5 JP 2008506758 A5 JP2008506758 A5 JP 2008506758A5 JP 2007522013 A JP2007522013 A JP 2007522013A JP 2007522013 A JP2007522013 A JP 2007522013A JP 2008506758 A5 JP2008506758 A5 JP 2008506758A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- heteroaryl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 N-piperidinyl Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0416168.3 | 2004-07-20 | ||
| GBGB0416168.3A GB0416168D0 (en) | 2004-07-20 | 2004-07-20 | Pyrmidothiophene compounds |
| PCT/GB2005/002816 WO2006008503A1 (en) | 2004-07-20 | 2005-07-18 | Pyrimidothiophene compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008506758A JP2008506758A (ja) | 2008-03-06 |
| JP2008506758A5 true JP2008506758A5 (https=) | 2008-09-04 |
| JP4891904B2 JP4891904B2 (ja) | 2012-03-07 |
Family
ID=32893845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522013A Expired - Fee Related JP4891904B2 (ja) | 2004-07-20 | 2005-07-18 | ピリミドチオフェン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090069336A1 (https=) |
| EP (1) | EP1773842A1 (https=) |
| JP (1) | JP4891904B2 (https=) |
| GB (1) | GB0416168D0 (https=) |
| WO (1) | WO2006008503A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101443334A (zh) * | 2005-12-21 | 2009-05-27 | 艾博特公司 | 抗病毒化合物 |
| WO2007084560A2 (en) * | 2006-01-17 | 2007-07-26 | Signal Pharmaceuticals, Llc | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| WO2008057246A2 (en) * | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| WO2008059368A2 (en) * | 2006-11-17 | 2008-05-22 | Pfizer Products Inc. | Fused 2-amino pyrimidine compounds and their use for the treatment of cancer |
| CA2679126A1 (en) | 2007-03-01 | 2008-09-04 | Chugai Seiyaku Kabushiki Kaisha | Macrocyclic compound |
| EP2155248B1 (en) * | 2007-04-12 | 2015-06-10 | The Brigham and Women's Hospital, Inc. | Targeting abcb5 for cancer therapy |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| TWI648281B (zh) | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| JP2017507969A (ja) * | 2014-03-11 | 2017-03-23 | ゴーダーヴァリ バイオリファイナリーズ リミテッド | がん幹細胞標的化合物 |
| US10336768B2 (en) | 2014-06-13 | 2019-07-02 | Yuma Therapeutics, Inc. | Pyrimidine compounds and methods using the same |
| CN106467545B (zh) * | 2015-08-20 | 2018-10-16 | 北大方正集团有限公司 | 一种噻吩并嘧啶化合物 |
| WO2022089449A1 (zh) * | 2020-10-26 | 2022-05-05 | 山东大学 | 一种特异性热休克蛋白90α亚型抑制剂制备及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US340183A (en) * | 1886-04-20 | yacoubenco | ||
| GB1188529A (en) * | 1966-06-09 | 1970-04-15 | Wellcome Found | Pyramidine Derivatives |
| JP4064671B2 (ja) | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| US7241890B2 (en) * | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| EA009920B1 (ru) * | 2003-08-29 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения пиримидотиофена |
-
2004
- 2004-07-20 GB GBGB0416168.3A patent/GB0416168D0/en not_active Ceased
-
2005
- 2005-07-18 EP EP05761541A patent/EP1773842A1/en not_active Withdrawn
- 2005-07-18 WO PCT/GB2005/002816 patent/WO2006008503A1/en not_active Ceased
- 2005-07-18 US US11/632,969 patent/US20090069336A1/en not_active Abandoned
- 2005-07-18 JP JP2007522013A patent/JP4891904B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008506758A5 (https=) | ||
| Rathore et al. | In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings | |
| JP2009535307A5 (https=) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2008535903A5 (https=) | ||
| JP2010527373A5 (https=) | ||
| JP2009526034A5 (https=) | ||
| EP3555078B1 (en) | Bisaryl heterocycles as nrf2 activators | |
| JP2007524707A5 (https=) | ||
| JP2008511601A5 (https=) | ||
| JP2005517006A5 (https=) | ||
| JP2004523585A5 (https=) | ||
| EA034201B1 (ru) | Соединения в качестве модуляторов ror-гамма | |
| JP2022521081A (ja) | Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体 | |
| JP2008546770A5 (https=) | ||
| TW470742B (en) | Benzimidazole derivatives, preparation and pharmaceutical compositions thereof | |
| EP4384506A1 (en) | Process for polyamide synthesis | |
| WO2014196328A1 (ja) | ヒドロキサム酸誘導体またはその塩 | |
| Liu et al. | 1H‐1, 2, 3‐triazole‐tethered isatin–coumarin hybrids: Design, synthesis and in vitro anti‐mycobacterial evaluation | |
| WO2008128045A1 (en) | Solid forms of (e) -1- (4- ( (ir, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl) ethanone oxime | |
| CN102131803A (zh) | (1r，2s，3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1，2，3，4-四醇的固体形式及其使用方法 | |
| US10370328B2 (en) | Oxindole compounds and pharmaceutical compositions thereof | |
| WO2023085396A1 (ja) | アルポート症候群を治療または予防するための医薬組成物 | |
| JP2010516779A5 (https=) | ||
| Popiołek et al. | Synthesis and in Vitro Antimicrobial Activity Screening of New 3‐Acetyl‐2, 5‐disubstituted‐1, 3, 4‐oxadiazoline Derivatives |